Introduction

In the modern world, with regards to the improvements in human life style and breakthroughs in medical sciences, vector-borne diseases such as malaria are still as public health challenge worldwide [1]. The most important reason is related to the movement capability of the vectors. Therefore, pathogens can be transported throughout the world [2]. Malaria is caused by protozoan parasites of the genus *Plasmodium* and transmitted to humans through the infected female *Anopheles* mosquito’s bites [3,4]. According to the WHO malaria report, in 2013, it has been estimated that 3.3 billion people are at risk of malaria infection and 1.2 billion are at high risk for this malignant malady. Furthermore, there were an estimated 584,000 out of 198 million cases of malaria happened entire of world led to deaths in 2013. In addition, malaria is the cause of more than 430,000 child’s deaths in Africa annually [5,6].

These undesirable statistics make that malaria be on the focus of international considerations to develop a comprehensive agenda for its control and global eradication. The first malaria eradication program was broken down for many reasons which the ignorance of the scientific comments and the lack of knowledge about endemic regions were the important factors.

With regards to the importance of malaria and its social and economic effects, in October 2007, the Bill and Melinda Gates Foundation summoned the Malaria Forum with cooperation with WHO and the Roll Back Malaria (RBM) for the second global malaria eradication program. More than 250 scientists were attended in 20 consultative meetings and published their solutions in different aspects such as drugs, vector control, modeling, etc [1].

Vaccine consultative group was introduced a new concept with the broad scope: Vaccines that Interrupt Malaria Transmission (VIMTs). They emphasized that VIMTs development is very necessary for endemic regions that have passed the pre-elimination and are toward to the eradication step [7].

VIMTs can be included one or more of these types of malaria vaccines: classical Transmission Blocking Vaccines (TBVs), pre-erythrocytic vaccines, erythrocytic vaccines and vector based vaccines. Most of the malaria vaccines which have been studied or those that are in clinical trials are related to parasite antigens. But, few studies have been performed that their targets are vector based antigens which are important in the sexual parasite development. The performed studies have showed that there are vector based cofactors which those are important in providing the parasite nutritional requirements or bio-barrier transferring [8-20].

Targeting the vector based antigens has some advantages in compare to parasite based TBVs which the most important of them are:

I. Vector based antigens are usually conserved proteins which are very important for mosquito surviving and those have very similar structure and function in different species [12,14,21]. Therefore, raised antibodies against a conserved protein of one species can be effective against the similar one in other species and if you find an antigen with these specifications, you can design and develop a universal TBV which is effective against different vectors with distinct geographical distribution.

II. Targeting the vector antigens may be affect the longevity and fecundity of mosquitoes. For example, lavazec et al. [16] reported that anti-CPBAg1 antibodies are reduced the number of *An. gambiae* eggs in compare to control groups. Therefore, affecting the mosquito fitness and population size can improve the impact of vaccination [16].

---

**Abstract**

Malaria, AIDS and tuberculosis are considered as the important infectious diseases in the world. Malaria has a close relationship with the climate and life style of the human. Therefore, malaria is known as the disease of the poor countries. With regards to its importance, WHO invited scientists with different specialties for programming the second global malaria eradication program? The recommendation of the vaccine consultative group was development of the vaccines that interrupt malaria transmission (VIMTs). VIMTs are composed of different type of vaccines which vector based TBVs are one of them. Vector based TBVs have advantages in compare other type VIMTs such as impact on the parasite life cycle and mosquito fitness simultaneously. Therefore, targeting the vector and parasite antigens simultaneously can be considered as a robust tool to reach the aim of global malaria eradication program.

**Keywords:** Malaria; Vaccines that interrupt malaria transmission; Transmission blocking vaccine; Vector borne diseases

**Abbreviations:** TBVs: Transmission Blocking Vaccines; VIMTs: Vaccines that Interrupt Malaria Transmission; WHO: World Health Organization; malEra: Malaria Eradication Program

**References**

[1] Raz A, Raz A, Raz A. Malaria Vector Based VIMTS: Challenges and Future. Int J Vaccines Vaccin 2016, 2(4): 00037.
III. One of the problems of selecting the plasmodium antigens is antigenic variation due to the pressure of immune system [22-24]. But, this problem will not be happened in the case of mosquito antigens.

IV. With regards to the benefits of vector based TBVs, but there are some challenging items for these types of TBVs as well. Because the human immune system is naturally not boosted against mosquito antigens, the selected antigens should be high immunogenic, robust adjuvants should be used for vaccination or revaccination should be considered periodically [11,25]. Furthermore, if targeting the vector based antigens affects the mosquito fitness [16], it will result to the increase of resistance population. Therefore, before application of these types of vaccines, well characterization and evaluation should be performed. Combination of more than one antigen can be reduced this effect as well.

Conclusion

With regards to the importance of malaria disease, WHO global malaria eradication program and malaria guidelines to reach the global eradication, development of the VIMTs is one of the necessities in this path. According to the specifications of the vector based VIMTs and the important role of the mosquitoes in malaria infection, these types of vaccines can be considered as an effective tool to reach and keep global eradication [26].

Acknowledgement

We would like to express our sincere gratitude to research deputy of Pasteur Institute of Iran for our supporting in malaria research and faculty member of Malaria and Vector Research Group and National Insectary of Iran for their valuable and fruitful comments.

References

1. Alonso PL, Brown G, Herrera AM, Binka F, Chitnis C, et al. (2011) A research agenda to underpin malaria eradication. PLoS Med 8(1): e1000406.

2. Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, et al. (2013) The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 382(9959): 900-911.

3. Cox FE (2010) History of the discovery of the malaria parasites and their vectors. Parasit Vectors 3(1): 5.

4. Tuteja R (2007) Malaria- an overview. The FEBS Journal 274(18): 4670-4679.

5. WHO (2014) World malaria report 2013: World Health Organization, Geneva.

6. WHO (2013) Test procedures for insecticide resistance monitoring in malaria vector mosquitoes. World Health Organization, Geneva, p. 39.

7. Abdulla S, Agre P, Alonso P, Herrera AM, Bassat Q, et al. (2001) A research agenda for malaria eradication: vaccines. PLoS Med 8(1): e1000398.

8. Abreu C, Ortigao RM (2010) Transmission blocking vaccines to control insect-borne diseases: a review. Mem Inst Oswaldo Cruz 105(1): 1-12.

9. Nikolaeva D, Draper SJ, Biswas S (2015) Toward the development of effective transmission-blocking vaccines for malaria. Expert Rev Vaccines 14(5): 653-660.

10. Draper SJ, Angov E, Horii T, Miller LH, Srinivasan P, et al. (2015) Recent advances in recombinant protein-based malaria vaccines. Vaccine 33(52): 7433-7443.

11. Lavazec C, Bourgoin C (2008) Mosquito-based transmission blocking vaccines for interrupting Plasmodium development. Microbes Infect 10(8): 845-849.

12. Dinglasan RR, Fields I, Shahabuddin M, Azad AF, Sacci JB (2003) Monoclonal antibody MG96 completely blocks Plasmodium yoelii development in Anopheles stephensi. Infect Immun 71(12): 6995-7001.

13. Kotsyfakis M, Sabatier EL, Kiamos SI, Mendoza J, Sindon RE, et al. (2005) Plasmodium berghei ookinetes bind to Anopheles gambiae and Drosophila melanogaster annexins. Mol Microbiol 57(1): 171-179.

14. Dinglasan RR, Kalume DE, Kanzok SM, Ghosh AK, Muratova O, et al. (2007) Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen. Proc Natl Acad Sci USA 104(33): 13461-13466.

15. Dinglasan RR, Alaganan A, Ghosh AK, Saito A, Kuppevelt VTH, et al. (2007) Plasmodium falciparum ookinetes require mosquito midgut chondroitin sulfate proteoglycans for cell invasion. Proc Natl Acad Sci USA 104(40): 15882-15887.

16. Lavazec C, Boudin C, Lacroix R, Bonnet S, Diop A, et al. (2007) Carboproteptidases B of Anopheles gambiae as targets for a Plasmodium falciparum transmission-blocking vaccine. Infect Immun 75(4): 1635-1642.

17. Raz A, Djadiid ND, Zakeri S (2013) Molecular characterization of the carboproteptidase B1 of Anopheles stephensi and its evaluation as a target for transmission-blocking vaccines. Infect Immun 81(6): 2206-2216.

18. Lázaro GM, Dinglasan RR, de la Cruz HHE, Rodríguez MH, Laclaustra M, et al. (2009) Anopheles gambiae Cytopeptor SRRCQ2, expression profile in the mosquito and its potential interaction with the malaria parasite Plasmodium berghei. Insect Biochem Mol Biol 39(5): 395-402.

19. Mathias DK, Jardin JG, Parish LA, Armistead JS, Trinh HV, et al. (2014) Differential roles of an Anopheline midgut GPI-anchored protein in mediating Plasmodium falciparum and Plasmodium vivax ookinete invasion. Infect Genet Evol 28: 635-647.

20. Rodríguez VJ, Ghosh AK, Kanzok SM, Dinglasan RR, Wang S, et al. Multiple pathways for Plasmodium ookinete invasion of the mosquito midgut. Proc Natl Acad Sci USA 111(4): E492-E500.

21. Dinglasan RR, Lorena MJ (2008) Flipping the paradigm on malaria transmission-blocking vaccines. Trends Parasitol 24(8): 364-370.

22. Hvid L (2010) The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development. Hum Vaccin 6(1): 84-99.

23. Drew DR, Hodder AN, Wilson DW, Foley M, Mueller I, et al. (2012) Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria. PLoS One 7(12): e15023.

24. Crompton PD, Pierce SK, Miller LH (2010) Advances and challenges in malaria vaccine development. J Clin Invest 120(12): 4168-4178.
25. Kielb KJ, Majadly F, Wu Y, Narum DL, Guo C, et al. (2007) Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci USA 104(1): 293-298.

26. Carter R (2001) Transmission blocking malaria vaccines. Vaccine 19(17): 2309-2314.